Study of efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric and young adult patients with sickle cell anemia.

Registry ID

EUCTR2016-002101-19

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Novartis Pharma Services AG

Start date

2016-11-22

Completion date

2020-04-27

Last update

2026-08-16

Conditions

• Sickle cell anemia

Summary

To determine the effect of canakinumab versus placebo on daily pain experienced by sickle cell anemia patients

Locations

• , , UK
• , , Germany

View on source registry